tbuckley/cabot-search huggingface dataset:
Prognostic factors and long-term outcome for uterine endometrial stromal sarcoma
Authors: C.-H. Lai, Y.-C. Wu, T.-I. Wu, S. Hsueh, H.-H. Chou, T.-C. Chang
Journal: Journal of Clinical Oncology (2005)

5150 Background: Endometrial stromal sarcoma (ESS) is a rare uterine neoplasm. Most studies included uterine sarcomas of different histologic types. The prognostic factors and long-term outcome for ESS are ill-defined. Methods: 47 cases with ESS or uterine sarcoma were retrieved from medical registry at Chang Gung Memorial Hospital from 1984 through 2003. After chart review and pathologic reconfirmation, 9 patients were excluded for wrong diagnosis or missing hospital charts/ paraffin blocks. A total of 38 patients were eligible for analysis (24 Stage I, 1 Stage II, 7 Stage III, and 6 Stage IV). Clinicopathological data and a panel of biomarker analyses including DNA flow cytometry, ER, PR, c-kit, CD10, MMP-2, and MIB-1 were analyzed for association with relapse or death. Results: The median follow-up time for survivors was 52 months (range, 6–174). Of the study patients, 14 developed recurrent or persistent disease. Among these 14 patients, 7 (50%) were successfully salvaged with multimodality treatment. The 5-year overall survival rate was 83.1% for the whole series. Advanced stage (II-IV vs I) was the only prognostic factor significantly associated with treatment failure. Advanced FIGO stage (II-IV), older age (>50 years old), CD 10-negative or low expression, and high mitotic count (cutoff point at 5 per 10 HPF) were identified as significant predictors for death. Conclusions: This study selected mitotic count, age, FIGO stage, and CD 10 expression as significant prognostic factors for ESS. Multimodality treatment could provide a substantial secondary control (50%) for ESS after primary treatment failed. No significant financial relationships to disclose.
WHO analgesic ladder: a good concept gone astray
Authors: Jane C Ballantyne, Eija Kalso, Cathy Stannard
Journal: BMJ (2016)

Our mistake is to treat chronic pain as if it were acute or end of life pain

In 1986, the World Health Organization (WHO) developed a simple model for the slow introduction and upward titration of analgesics, which became known as the WHO analgesic stepladder.1 Before this, people were dying in unnecessary pain because drug regulations introduced earlier in the century had increased the stigma and fear associated with both prescribing and taking opioids.

The underlying principle was that analgesics should be used incrementally, starting with non-opioids, progressing through mild and finally strong opioids, dosed in accordance with the patient’s reported pain intensity. It was expected that opioids would be needed in increasing doses to overcome pain as cancer progressed. The goal was to allow patients to be as comfortable and interactive as possible during the short march towards death. Risks of addiction and hastened death were accepted in the principle of double effect: comfort is paramount.2

The stepladder approach had tremendous value when it was introduced because it legitimised the use of opioids, overcoming prejudicial …
Abstract 18277: Bioadhesive and Biodegradable Hyaluronic Acid-Serum Hydrogel Promotes Cardiac Regeneration
Authors: Angel T Chan, Styliani Vakrou, Kirubel Woldemichael, Junaid Afzal, Andrew Rittenbach, Xiaoping Lin, Sophia Brown, Richard Wahl, Brian O’Rourke, Theodore P Abraham, Benjamin M Tsui, Charles J Steenbergen, Jennifer H Elisseeff, M. R Abraham
Journal: Circulation (2013)

Cellular cardiomyoplasty is limited by low levels of engraftment due to cell egress from injection site and death due to anoikis/necrosis. We hypothesized that tissue-engineered scaffolds that promote rapid cell adhesion would promote transplanted cell engraftment. We custom-designed stem cell niches, examined encapsulated stem cell viability, proliferation and 18 FDG uptake. Acute cardiac retention was measured by cut/count after transplantation of 18 FDG labeled rat cardiosphere derived cells (CDCs), in vivo transplanted cell bioenergetics by dual isotope SPECT/CT imaging of Na-Iodide symporter + CDCs (after 99m Tc-pertechnetate administration), and chronic engraftment by bioluminescence imaging (BLI) of luciferase + CDCs; LV function was assessed by echocardiography. Crosslinking of N-hydroxysuccinimide-derivatized hyaluronic acid with autologous serum yielded bioadhesive, biodegradable hydrogels (HA:Ser) that promoted survival and proliferation of mouse embryonic stem cells, human mesenchymal stem cells, and CDCs (viability: 99%, 93%, and 95%; proliferation: 759%, 126%, and 322%, respectively at d7; n=3, p&lt; 0.05). I n vitro 18 FDG uptake revealed rapid depression (0.13±0.01%ID/μg DNA) following trypsinization and prompt restoration by encapsulation in hydrogels (0.36±0.04%ID/μg DNA; n=4, p&lt; 0.05); in vivo 99m Tc uptake of encapsulated CDCs at 1hr was 2.4fold higher than transplantation of suspended CDCs. Hydrogels boosted acute cell retention following intra-myocardial transplantation (hydrogel: 92±3%; suspended cells: 15±5%), in vivo BLI revealed CDC proliferation (20%increase) in hydrogels and cell loss (99% decrease; n=3, p &lt;0.05) in the suspended cell group. Echocardiogram revealed increased in LVEF of 0.69±1.9% in control, 10.33±2.1% in epicardial HA:Ser and 12.9±4.1% in intra-myocardial HA:Ser (n=7, p &lt;0.05) at d28 compared to d1 post-MI. Hydrogels also induced 5fold higher angiogenesis than controls. In conclusion, HA:Ser hydrogels can be injected intramyocardially or applied epicardially as patches to beating hearts. These hydrogels induce rapid stem cell attachment, acute retention, in vivo proliferation and improve cardiac function following myocardial infarction.
Sibling Comparisons and Confounding in Autism Epidemiological Studies—Reply
Authors: Eileen A. Curran, Louise C. Kenny, Ali S. Khashan
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling
Authors: Emma I Andersson, Leopold Sellner, Malgorzata Oles, Tea Pemovska, Paavo Pietarinen, Anneli Lauhio, Katarzyna Tomska, Carlos Cuesta-Mateos, Edgar Faber, Tim H. Brummendorf, Olli Kallioniemi, Kimmo Porkka, Caroline A Heckman, Wolfgang Huber, Krister Wennerberg, Thorsten Zenz, Satu Mustjoki
Journal: Blood (2014)
Posterior lamellar versus bilamellar tarsal rotation surgery for trachomatous trichiasis in Ethiopia: a randomised controlled trial
Authors: Esmael Habtamu, Tariku Wondie, Sintayehu Aweke, Zerihun Tadesse, Mulat Zerihun, Zebideru Zewudie, Amir Bedri Kello, Chrissy H Roberts, Paul M Emerson, Robin L Bailey, David C W Mabey, Saul N Rajak, Kelly Callahan, Helen A Weiss, Matthew J Burton
Journal: The Lancet Global Health (2016)

Eyelid surgery is done to correct trachomatous trichiasis to prevent blindness. However, recurrent trichiasis is frequent. Two procedures are recommended by WHO and are in routine practice: bilamellar tarsal rotation (BLTR) and posterior lamellar tarsal rotation (PLTR). This study was done to identify which procedure gives the better results.A randomised, controlled, single masked clinical trial was done in Ethiopia. Participants had upper lid trachomatous trichiasis with one or more eyelashes touching the eye or evidence of epilation, in association with tarsal conjunctival scarring. Exclusion criteria were age less than 18 years, recurrent trichiasis after previous surgery, hypertension, and pregnancy. Participants were randomly assigned (1:1) to either BLTR or PLTR surgery, stratified by surgeon. The sequences were computer-generated by an independent statistician. Surgery was done in a community setting following WHO guidelines. Participants were examined at 6 months and 12 months by assessors masked to allocation. The primary outcome was the cumulative proportion of individuals who developed recurrent trichiasis by 12 months. Primary analyses were by modified intention to treat. The intervention effect was estimated by logistic regression, controlled for surgeon as a fixed effect in the model. The trial is registered with the Pan African Clinical Trials Registry (number PACTR201401000743135).1000 participants with trichiasis were recruited, randomly assigned, and treated (501 in the BLTR group and 499 in the PLTR group) between Feb 13, 2014, and May 31, 2014. Eight participants were not seen at either 6 month or 12 month follow-up visits and were excluded from the analysis: three from the PLTR group and five from the BLTR group. The follow-up rate at 12 months was 98%. Cumulative recurrent trichiasis by 12 months was more frequent in the BLTR group than in the PLTR group (110/496 [22%] vs 63/496 [13%]; adjusted odds ratio [OR] 1·96 [95% CI 1·40-2·75]; p=0·0001), with a risk difference of 9·50% (95% CI 4·79-14·16).PLTR surgery was superior to BLTR surgery for management of trachomatous trichiasis, and could be the preferred procedure for the programmatic management of trachomatous trichiasis.The Wellcome Trust.
Ex-Th17 Foxp3+ T cells - a novel subset of Foxp3+ T cells induced in cancer
Authors: Stephanie Downs-Canner, Roshni Ravindranathan, Robert P Edwards, Pawel Kalinski, Kunle Odunsi, David L Bartlett, Natasa Obermajer
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Th17 and regulatory T (Treg) cells are integral in maintaining immune homeostasis and Th17-Treg misbalance associates with inflammation. We demonstrate that in addition to natural (n)Treg and induced (i)Treg cells developed from naïve precursors, Th17 cells are a novel source of
Adjuvant chemotherapy in pathologic Stage II nonseminomatous testicular cancer: are two cycles of etoposide-cisplatin a standard option?
Authors: S Culine, J P Droz
Journal: Journal of Clinical Oncology (1996)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.7.2187 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8683254 Adjuvant chemotherapy in pathologic Stage II nonseminomatous testicular cancer: are two cycles of etoposide-cisplatin a standard option? S CulinexS CulineSearch for articles by this author , J P DrozxJ P DrozSearch for articles by this author https://doi.org/10.1200/JCO.1996.14.7.2187 PDF "Adjuvant chemotherapy in pathologic Stage II nonseminomatous testicular cancer: are two cycles of etoposide-cisplatin a standard option?." Journal of Clinical Oncology, 14(7), pp. 2187–2188© 1996 by American Society of Clinical Oncology
Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer
Authors: Takahiro Karasaki, Kazuhiro Nagayama, Mitsuaki Kawashima, Noriko Hiyama, Tomonori Murayama, Hideki Kuwano, Jun-ichi Nitadori, Masaki Anraku, Masaaki Sato, Manami Miyai, Akihiro Hosoi, Hirokazu Matsushita, Shingo Kikugawa, Ryo Matoba, Osamu Ohara, Kazuhiro Kakimi, Jun Nakajima
Journal: Journal of Thoracic Oncology (2015)
MACC1 Induces Tumor Progression in Transgenic Mice and Colorectal Cancer Patients via Increased Pluripotency Markers Nanog and Oct4
Authors: Clara Lemos, Markus S. Hardt, Manisha Juneja, Cynthia Voss, Susann Förster, Boris Jerchow, Wolfram Haider, Hendrik Bläker, Ulrike Stein
Journal: Clinical Cancer Research (2016)

We have previously identified the gene MACC1 as a strong prognostic biomarker for colorectal cancer metastasis and patient survival. Here, we report for the first time the generation of transgenic mouse models for MACC1.We generated mice with transgenic overexpression of MACC1 in the intestine driven by the villin promoter (vil-MACC1) and crossed them with Apc(Min) mice (vil-MACC1/Apc(Min)).vil-MACC1/Apc(Min) mice significantly increased the total number of tumors (P = 0.0056). This was particularly apparent in large tumors (≥3-mm diameter; P = 0.0024). A detailed histopathologic analysis of these lesions demonstrated that the tumors from the vil-MACC1/Apc(Min) mice had a more invasive phenotype and, consequently, showed a significantly reduced survival time than Apc(Min) mice (P = 0.03). Molecular analysis revealed an increased Wnt and pluripotency signaling in the tumors of vil-MACC1/Apc(Min) mice. Specifically, we observed a prominent upregulation of the pluripotency markers Oct4 and Nanog in these tumors compared with Apc(Min) controls. Finally, we could also validate that Oct4 and Nanog are regulated by MACC1 in vitro and strongly correlate with MACC1 levels in a cohort of 60 tumors of colorectal cancer patients (r = 0.7005 and r = 0.6808, respectively; P > 0.0001 and P > 0.0002, respectively).We provide proof of principle that MACC1-induced tumor progression in colorectal cancer acts, at least in part, via the newly discovered MACC1/Nanog/Oct4 axis. These findings might have important implications for the design of novel therapeutic intervention strategies to restrict tumor progression. Clin Cancer Res; 22(11); 2812-24. ©2016 AACR.
The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era
Authors: T Kobayashi, J Kuroda, I Yokota, K Tanba, T Fujino, S Kuwahara, R Isa, J Yamaguchi, E Kawata, T Akaogi, H Uchiyama, H Kaneko, N Uoshima, Y Kobayashi, S Teramukai, M Taniwaki
Journal: Blood Cancer Journal (2016)

The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era
Abstract P3-04-12: Pathological and molecular effects of lack of PR expression in ER positive breast tumors
Authors: Rachel E Ellsworth, Allyson L Valente, Matthew T Hueman, Craig D Shriver
Journal: Cancer Research (2015)

Abstract Background: Evaluation of hormone receptor status is standard in breast cancer diagnosis; however, prognosis and treatment decisions are frequently based on the status of the estrogen receptor (ER) but not the progesterone receptor (PR). To determine how PR status affects etiology and outcome of ER positive tumors, pathological and molecular characteristics of ER+PR+ and ER+PR- tumors were assessed. Methods: ER and PR positivity were defined as &amp;gt;10% staining and all patients with ER+PR+ and ER+PR- were identified. Differences in pathological characteristics were evaluated using Chi-square tests with P&amp;lt;0.05 defining significance. RNA was isolated from primary tumor cells after laser-microdissection and hybridized to U133A 2.0 arrays. Gene expression data was analyzed by ANOVA using a false-detection rate &amp;lt;0.5 and &amp;gt;2.0-fold difference to define significance. Results: Of the 1,139 ER+ tumors, 21% were PR-. Age at diagnosis, ethnicity, tumor size, lymph node and Ki67 status did not differ between groups; however, patients with PR- tumors were significantly more likely to be diagnosed at an advanced stage, with high-grade, HER2 positive tumors, and more likely to die of disease. Thirty genes were differentially expressed including significantly higher expression levels of APOBEC3B and significantly lower expression of GREB1, MAPT and SCUBE2. Discussion: Expression of PR significantly alters tumor biology and clinical outcomes of ER positive tumors. Genes with altered expression in PR negative tumors are associated with more aggressive characteristics, such as increased invasion, kataegis, regulation of ER and response to tamoxifen. Thus, PR status is critical in the diagnosis and treatment of patients with ER positive breast tumors. Citation Format: Rachel E Ellsworth, Allyson L Valente, Matthew T Hueman, Craig D Shriver. Pathological and molecular effects of lack of PR expression in ER positive breast tumors [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P3-04-12.
Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia
Authors: MC Le Bousse-Kerdiles, S Chevillard, A Charpentier, N Romquin, D Clay, F Smadja-Joffe, V Praloran, B Dupriez, JL Demory, C Jasmin, MC Martyre
Journal: Blood (1996)
Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL
Authors: Romain Guièze, Pauline Robbe, Ruth Clifford, Sophie de Guibert, Bruno Pereira, Adele Timbs, Marie-Sarah Dilhuydy, Maite Cabes, Loïc Ysebaert, Adam Burns, Florence Nguyen-Khac, Frédéric Davi, Lauren Véronèse, Patricia Combes, Magali Le Garff-Tavernier, Véronique Leblond, Hélène Merle-Béral, Reem Alsolami, Angela Hamblin, Joanne Mason, Andrew Pettitt, Peter Hillmen, Jenny Taylor, Samantha J. L. Knight, Olivier Tournilhac, Anna Schuh
Journal: Blood (2015)
Abstract 15225: Delayed Hyper-Enhancement on Cardiac MRI in Patients with Severe Aortic Stenosis is Related with Attenuated Improvement of Left Ventricle Geometry and Diastolic Function
Authors: Junbeom Park, Hyuk-Jae Chang, Young-Jin Kim, Chi Young Shim, Geu-ru Hong, Joung-Won Ha, Namsik Chung
Journal: Circulation (2012)
Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes
Authors: Ralf E. Harskamp, John H. Alexander, T. Bruce Ferguson, Rebecca Hager, Michael J. Mack, Brian Englum, Daniel Wojdyla, Phillip J. Schulte, Nicholas T. Kouchoukos, Robbert J. de Winter, C. Michael Gibson, Eric D. Peterson, Robert A. Harrington, Peter K. Smith, Renato D. Lopes
Journal: Circulation (2016)

The internal mammary artery (IMA) is the preferred conduit for bypassing the left anterior descending (LAD) artery in patients undergoing coronary artery bypass grafting. Systematic evaluation of the frequency and predictors of IMA failure and long-term outcomes is lacking.The Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV trial participants who underwent IMA-LAD revascularization and had 12- to 18-month angiographic follow-up (n=1539) were included. Logistic regression with fast false selection rate methods was used to identify characteristics associated with IMA failure (≥75% stenosis). The relationship between IMA failure and long-term outcomes, including death, myocardial infarction, and repeat revascularization, was assessed with Cox regression. IMA failure occurred in 132 participants (8.6%). Predictors of IMA graft failure were LAD stenosis <75% (odds ratio, 1.76; 95% confidence interval, 1.19-2.59), additional bypass graft to diagonal branch (odds ratio, 1.92; 95% confidence interval, 1.33-2.76), and not having diabetes mellitus (odds ratio, 1.82; 95% confidence interval, 1.20-2.78). LAD stenosis and additional diagonal graft remained predictive of IMA failure in an alternative model that included angiographic failure or death before angiography as the outcome. IMA failure was associated with a significantly higher incidence of subsequent acute (<14 days of angiography) clinical events, mostly as a result of a higher rate of repeat revascularization.IMA failure was common and associated with higher rates of repeat revascularization, and patients with intermediate LAD stenosis or with an additional bypass graft to the diagonal branch had increased risk for IMA failure. These findings raise concerns about competitive flow and the benefit of coronary artery bypass grafting in intermediate LAD stenosis without functional evidence of ischemia.URL: http:/www.clinicaltrials.gov. Unique identifier: NCT00042081.
Isokinetic evaluation of knee extensors and flexors in patients with unilateral symptomatic gonarthrosis
Authors: Yves Henrotin, Jean-Louis Croisier, R Dumont, O Debry, Jean-Pierre Huskin, JE Dubuc, JP Leflot, Jean-Yves Reginster, Jean-Michel Crielaard
Journal: Annals of the Rheumatic Diseases (2000)
Production of Urinary Bladder Carcinomas in Male Hamsters by N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide, N-[4-(5-Nitro-2-furyl)-2-thiazolyl]-acetamide, or Formic Acid 2-[4-(5-Nitro-2-furyl)-2-thiazolyi]hydrazide2
Authors: William A. Croft, George T. Bryan
Journal: JNCI Journal of the National Cancer Institute (1973)

N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide (FANFT), N-[4-(5-nitro-2-furyl)-2-thiazolyl]-acetamide (NFTA), or formic acid 2-[4-(5-nitro-2-furyl)-2-thiazolyl]hydrazide (FNT), potent carcinogens for the rat, mouse, and dog, were fed at 0.1% of the diet to male weanling Syrian golden hamsters for 48 weeks, followed by control diet for an additional 22 weeks. The incidences of tumors were: FANFT—23 of 24 hamsters with urinary bladder transitional carcinomas, 5 of 24 with forestomach squamouscell papillomas, and 1 of 24 with an adrenal adenoma,- NFTA—16 of 24 hamsters with urinary bladder transitional cell carcinomas, 1 of 24 with an adrenal adenoma, and 1 of 24 with an adrenal adenocarci-noma; and FNT—9 of 24 hamsters with urinary bladder transitional cell carcinomas, 13 of 24 with fore-stomach squamous cell papillomas, 6 of 24 with adrenal adenomas, and 1 of 24 with a renal transitional cell carcinoma. Only 1 adrenal adenoma was found in the untreated hamsters. These data demonstrate that hamsters are as susceptible as other species to the carcinogenicity of 5-nitrofurans.
Asymptomatic Valvular Heart Disease: Can Earlier Intervention Be Justified?
Authors: Patrick O'Gara
Journal: Circulation (2012)

Advances in cardiac surgical techniques and peri-operative management over the past 2 decades have led to improved patient outcomes and frame-shifted the timing of operation to an earlier stage in the natural history of valvular heart disease. Both US and European guidelines recommend valve replacement surgery for asymptomatic patients with left ventricular systolic dysfunction as defined by the specific valve lesion. The debate regarding the optimal approach to the patient with severe valvular heart disease and preserved systolic function has yet to be informed by prospective randomized trials, performance of which is challenged by lack of equipoise, cost, and funding. Individual considerations in the older population are particularly challenging, given the trade-offs between surgical risk and the desire to maximize the time over which a full, functional recovery might be enjoyed. A mandate that surgery for the asymptomatic patient be performed in centers of excellence cannot be enforced in the absence of clear and transparent definitions. Lastly, the excitement surrounding trans-catheter valve intervention poses a risk for its application in increasingly healthier patient populations. It is hoped that the heart team approach will enable balanced decision-making in collaboration with an informed patient, until properly designed randomized prospective studies are completed. A national effort will be required to reach this goal.
Delivery strategies to control inflammatory response: Modulating M1–M2 polarization in tissue engineering applications
Authors: Mario Moisés Alvarez, Julie C. Liu, Grissel Trujillo-de Santiago, Byung-Hyun Cha, Ajaykumar Vishwakarma, Amir M. Ghaemmaghami, Ali Khademhosseini
Journal: Journal of Controlled Release (2016)